

PI Name	Protocol No.	Title	CRC
<b>ADULT TRIALS</b>			
<b>THERAPEUTIC</b>			
<b>BRAIN</b>			
Wagner, Henry	PSHCI-10-026	Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis Coordinated by the Radiation Therapy Oncology Group ( <b>RTOG 0631</b> )	Kathleen Rizzo 717-531-0003 ext 289630
Aergawi, Dawit	PSHCI-15-081	An Open-Label, Single-Arm, Phase II Study of Pertuzumab with High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients with HER2-Positive Metastatic Breast Cancer ( <b>PATRICIA</b> )	Cynthia Campbell-Baird, 717-531-5777 & pager 1738
Aergawi, Dawit	PSHCI-16-016	A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification ( <b>Intelligence 1</b> )	Cynthia Campbell-Baird, 717-531-5777 & pager 1738
Aergawi, Dawit	PSCI-16-062	A Phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy	Nikita Shah 717-531-0003 ext 282645
Black, David	PSCI-16-064	NeMeRe, a Multi-Institutional Retrospective and Prospective Registry of Neoplastic Meningitis in Adults	Nicole Matthews 717-531-6069
<b>BREAST</b>			
Truica, Cristina	PSHCI-13-002	Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer ( <b>S1207</b> )	Lea May 717-531-0003 ext 285550 pager 3973
Truica, Cristina	PSHCI-13-041	A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms ( <b>AIMSS</b> ) ( <b>E1Z11</b> )	Lea May 717-531-0003 ext 285550 pager 3973
Schetter, Susann	PSHCI-13-083	Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer	Swati Shah 717-531-6069
Wagner, Henry	PSHCI-13-084	A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy ( <b>B-51 and R1304</b> )	Lea May 717-531-0003 ext 285550 pager 3973
Truica, Cristina	PSHCI-13-101	Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant Treatment ( <b>ALTERNATE</b> ) in Postmenopausal Women: A Phase III Study	Lea May 717-531-0003 ext 285550 pager 3973
Truica, Cristina	PSHCI-14-103	Phase III Study Evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients With Hormone-receptor-positive, HER2-normal Primary Breast Cancer With High Relapse Risk After Neoadjuvant Chemotherapy " <b>PENELOPEB</b> "	Lea May 717-531-0003 ext 285550 pager 3973

PI Name	Protocol No.	Title	CRC
Widders, Kristine	PSHCI-14-105	A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy ( <b>A011202</b> )	Lea May 717-531-0003 ext 285550 pager 3973
Truica, Cristina	PSHCI-14-106	A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Postmenopausal Patients With Hormone Receptor-Positive Advanced Breast Cancer ( <b>E2112</b> )	Lea May 717-531-0003 ext 285550 pager 3973
Cream, Leah	PSHCI-14-107	A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy (OlympiA)	Lea May 717-531-0003 ext 285550 pager 3973
Truica, Cristina	PSHCI-15-059	EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy	Lea May 717-531-0003 ext 285550 pager 3973
Truica, Cristina	PSHCI-15-060	A Randomized Phase III trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide followed by Weekly Paclitaxel with or without Carboplatin in Women with Node-Positive or High-Risk Node-Negative Triple Negative Invasive Breast Cancer	Lea May 717-531-0003 ext 285550 pager 3973
Truica, Cristina	PSCI-16-031	With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer	Lea May 717-531-0003 ext 285550 pager 3973
Truica, Cristina	PSCI-16-053	A Single Arm Phase II Study of Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016	Lea May 717-531-0003 ext 285550 pager 3973
Truica, Cristina	PSCI-16-055	A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor (TRINITI-1)	Lea May 717-531-0003 ext 285550 pager 3973
Truica, Cristina	PSCI-16-067	Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer	Lea May 717-531-0003 ext 285550 pager 3973
Schetter, Susann	PSCI-16-143	Comparison of 3D Mammography to a Fast MRI in Breast Cancer Screening in Women with Dense Breasts	Rebecca Jordan 717-531-0003 ext281205

PI Name	Protocol No.	Title	CRC
<b>CARCINOID SYNDROM (None as of 05/17/2017)</b>			
<b>GI</b>			
Moyer, Matthew	PSHCI-10-109	Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts	Matthew Moyer 717-531-3694
Yee, Nelson Shu-sang	PSHCI-14-032	Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma	Irina Geier 717-531-0003 ext 4300
Glantz, Michael	PSHCI-15-044	Risk Factors for CIPN Following an Oxaliplatin-Containing Chemotherapy Regimen in Colorectal Cancer Patients	Sara Langan slangan@hmc.psu.edu
Almokadem, Salah	PSHCI-15-105	A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-Line Standard Therapy (KEYNOTE-181)	Jennifer Hallman 717-531-0003 ext 287412
Yee, Nelson Shu-sang	PSHCI-15-109	Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas	Irina Geier 717-531-0003 ext 4300
Yee, Nelson Shu-sang	PSHCI-15-110	A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors	Kathleen Rizzo 717-531-0003 ext 289630
Jia, Yuxia; Schmitz, Kathryn, H	PSHCI-15-114	Resistance Training to Decrease Chemotoxicity in Colon Cancer Patients	Wanda Neidig 717-531-1002
Yee, Nelson Shu-sang	PSHCI-16-025	InterAACT - An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5-Fluorouracil Versus Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease	Irina Geier 717-531-0003 ext 4300
Jia, Yuxia	PSCI-16-050	A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer	Irina Geier 717-531-0003 ext 4300
Yee, Nelson Shu-sang	PSCI-16-075	A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	Kathleen Rizzo 717-531-0003 ext 289630
Yee, Nelson Shu-sang	PSCI-16-091	An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients with Advanced or Metastatic Hepatocellular Carcinoma	Irina Geier 717-531-0003 ext 4300

PI Name	Protocol No.	Title	CRC
<b>GU</b>			
Joshi, Monika	PSHCI-13-090	A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer ( <b>S1216</b> )	Kathleen Rizzo 717-531-0003 ext 289630
Joshi, Monika	PSHCI-14-040	A Phase 2 Randomized, Double-Blind Study of Dalantercept plus Axitinib Compared to Placebo plus Axitinib in Patients with Advanced Renal Cell Carcinoma ( <b>Acceleron Pharma, Inc</b> )	Kathleen Rizzo 717-531-0003 ext 289630
Joshi, Monika	PSHCI-15-002	A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with FGFR Genomic Alterations	Kathleen Rizzo 717-531-0003 ext 289630
Raman, Jay	PSHCI-15-095	Evaluation of the ACS NSQIP Surgical Risk Calculator in Patients Undergoing Radical Nephroureterectomy for Upper Tract TCC	jraman@pennstatehealth.psu.edu
Yee, Nelson Shu-sang	PSHCI-15-110	A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors	Kathleen Rizzo 717-531-0003 ext 289630
Kaag, Matthew	PSCI-16-048	A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd-Interferon (IFN)/Syn3) Administered Intravesically to Patients With High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)	Kathleen Rizzo 717-531-0003 ext 289630
Joshi, Monika	PSCI-16-059	Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients with Urothelial Cancer (T2-4 N0-2 M0) of the Bladder:Big Ten Cancer Research Consortium BTCRC-GU15-023	Kathleen Rizzo 717-531-0003 ext 289630
Joshi, Monika	PSCI-16-096	A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection	Kathleen Rizzo 717-531-0003 ext 289630
Aregawi, Dawit	PSCI-16-097	Phase 1B, Multicenter, Open-Label Study of Marizomib Combined with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma	Nikita Shah 717-531-0003 ext 282645
Joshi, Monika	PSCI-16-107	A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma	Kathleen Rizzo 717-531-0003 ext 289630
Joshi, Monika	PSCI-16-113	A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy	Kathleen Rizzo 717-531-0003 ext 289630
<b>GYN</b>			
Kesterson, Joshua	PSHCI-09-064	A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer ( <b>GOG 213</b> )	Ann Gelder 717-531-8144 pager 1488
Kesterson, Joshua	PSHCI-09-073	A Randomized phase III trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma ( <b>GOG 258</b> )	Ann Gelder 717-531-8144 pager 1488



PI Name	Protocol No.	Title	CRC
<b>HEAD AND NECK</b>			
Almokadem, Salah	PSCI-16-128	A Phase II Study OF Enzalutamide (NSC# 766085) for patients with Androgen receptor positive salivary cancers	Rebecca Hale 717-531-1003 pager 3656
Almokadem, Salah	PSCI-17-003	A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)	Rebecca Hale 717-531-1003 pager 3656
<b>HEMATOLOGY/OTHER</b>			
Rybka, Witold	PSHCI-13-029	A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies	Brian Couch 717-531-0003 ext 285861 pager 0406
Greiner, Robert, J	PSCI-16-078	A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Venous-occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant	COG Contact 717-531-6012
<b>LEUKEMIA</b>			
McGregor, Lisa	PSHCI-11-097	A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006,IND#69896, NSC# 724772 for Patients with High Allelic Ratio FLT3/ITD	COG Contact 717-531-6012
Claxton, David	PSHCI-13-097	A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults	Brian Couch 717-531-0003 ext 285861 pager 0406
Claxton, David	PSHCI-13-100	Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia(AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplant (HSCT) Consolidation ( <b>Ambit Biosciences</b> )	Christine Capper, 717-531-0003 ext 285453
Claxton, David	PSHCI-15-054	A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation	Christine Capper, 717-531-0003 ext 285453
Pu, Jeffrey	PSHCI-15-065	A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia	Brian Couch 717-531-0003 ext 285861 pager 0406
Brown, Valerie	PSHCI-15-075	A Phase 2, Multi-center, Single-arm, Open-label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid®) in Pediatric Subjects 1 to ≤ 18 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia	Kathryn Byrnes 717-531-3098
Palmisiano, Neil	PSHCI-15-093	A Phase I, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-Cell Lineage Acute Lymphoblastic Leukemia (B-ALL)	Brian Couch 717-531-0003 ext 285861 pager 0406
Pu, Jeffrey	PSCI-16-005	A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy	Brian Couch 717-531-0003 ext 285861 pager 0406

PI Name	Protocol No.	Title	CRC
Claxton, David	PSCI-16-032	A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY)	Brian Couch 717-531-0003 ext 285861 pager 0406
Pu, Jeffrey	PSCI-16-036	A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304	Brian Couch 717-531-0003 ext 285861 pager 0406
Pu, Jeffrey	PSCI-16-037	A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination With TGR-1202 Compared to Obinutuzumab in Combination With Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)	Brian Couch 717-531-0003 ext 285861 pager 0406
Claxton, David	PSCI-16-038	A Phase 2/3 Multicenter, Open-label, 3 arm, 2 stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine, and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy	Christine Capper, 717-531-0003 ext 285453
<b>LYMPHOMA</b>			
Rybka, Witold	PSHCI-14-059	A Study to Evaluate Biomarkers of Sensitivity and Resistance in Patients with Relapsed/Refractory Hodgkin Lymphoma Who Are Treated with Brentuximab Vedotin	Christine Capper, 717-531-0003 ext 285453
Rizvi, Syed	PSHCI-14-113	Phase II Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) retinamide, 4-HPR) Emulsion for Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)	Brian Couch 717-531-0003 ext 285861 pager 0406
Rybka, Witold	PSHCI-16-027	Phase Ib Trial of Pembrolizumab(MK-3475)in Combination with Dinaciclib(MK-7965)in Subjects with Hematologic Malignancies (KEYNOTE-155)	Brian Couch 717-531-0003 ext 285861 pager 0406

PI Name	Protocol No.	Title	CRC
<b>MDS (None as of 05/17/2017)</b>			
<b>MELANOMA</b>			
Neves, Rogerio	PSHCI-09-052	The Collection of Blood, Tissue and Phenotypic Data in Patients Diagnosed with Skin Cancers and Subsequent Metastases for Inclusion in a Repository and Use in Outcome Studies	Rogério Neves 717-531-8371, rneves@psu.edu
Drabick, Joseph	PSHCI-14-057	A Phase 1/2 Study of the Concomitant Administration of Indoximod plus Ipilimumab for Adult Patients with Metastatic Melanoma	Jennifer Hallman 717-531-0003 ext 287412
Drabick, Joseph	PSHCI-15-069	A Phase 1b, Open-label, Multicenter, Dose-escalation Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma	Jennifer Hallman 717-531-0003 ext 287412
Drabick, Joseph	PSHCI-16-001	A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma	Jennifer Hallman 717-531-0003 ext 287412
Mallett, Kimberly, A	PSCI-16-051	Efficacy of a Behavioral Intervention to Reduce Skin Cancer Risk Among Patients	Sarah Ackerman 814-865-4222

PI Name	Protocol No.	Title	CRC
<b>MYELOFIBROSIS (None as of 05/17/2017)</b>			
<b>MYELOMA</b>			
Talamo, Giampaolo	PSHCI-11-118	Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma	Brian Couch 717-531-0003 ext 285861 pager 0406
Talamo, Giampaolo	PSHCI-13-052	A Phase 2, Multicenter, Multi-Cohort, Open-Label Study of Pomalidomide in Combination with Low-Dose Dexamethasone or Pomalidomide in Combination with Low-Dose Dexamethasone and Daratumumab in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide Based Therapy in the First or Second Line Setting (CC-4047-MM-014)(PSHCI 13-052)	Brian Couch 717-531-0003 ext 285861 pager 0406
Rybka, Witold	PSHCI-14-027	Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)	Brian Couch 717-531-0003 ext 285861 pager 0406
Rybka, Witold	PSHCI-16-027	Phase Ib Trial of Pembrolizumab(MK-3475)in Combination with Dinaciclib(MK-7965)in Subjects with Hematologic Malignancies (KEYNOTE-155)	Brian Couch 717-531-0003 ext 285861 pager 0406
<b>PHASE I</b>			
Belani, Chandra	PSHCI-14-065	A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination with Standard Doublet Therapy of Pemetrexed/Carboplatin in Patients with Stage IV (TNM M1a and M1b) Recurrent or Metastatic Non-Squamous Non-Small Cell Lung Cancer ( <b>Helix BioPharma</b> )	Rebecca Hale 717-531-1003 pager 3656
Yee, Nelson Shu-sang	PSHCI-15-053	A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD 1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies	Irina Geier 717-531-0003 ext 4300
Belani, Chandra	PSHCI-15-107	A Phase I/II Study of Glembatumumab Vedotin in Patients with gpNMB-Expressing, Advanced or Metastatic Squamous Cell Carcinoma of the Lung	Rebecca Hale 717-531-1003 pager 3656
Yee, Nelson Shu-sang	PSHCI-15-110	A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors	Kathleen Rizzo 717-531-0003 ext 289630
Glantz, Michael	PSHCI-16-011	Immunological targeting of CD-133 in recurrent glioblastoma: A multi-center Phase I translational and clinical study of an autologous CD-133 DC vaccine	Cindy Campbell Baird 717-531-5777 cbaird@hmc.psu.edu
Yee, Nelson Shu-sang	PSCI -16-020	A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications	Lea May 717-531-0003 ext 285550 pager 3973
Rybka, Witold	PSHCI-16-027	Phase Ib Trial of Pembrolizumab(MK-3475)in Combination with Dinaciclib(MK-7965)in Subjects with Hematologic Malignancies (KEYNOTE-155)	Brian Couch 717-531-0003 ext 285861 pager 0406
<b>PREVENTION (None as of 05/17/2017)</b>			
<b>SARCOMA</b>			
McGregor, Lisa	PSHCI-15-031	Randomized Phase III Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma	COG Contact 717-531-6012
Drabick, Joseph	PSCI-16-057	A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma	Kathleen Rizzo 717-531-0003 ext 289630



PI Name	Protocol No.	Title	CRC
<b>SOLID TUMOR</b>			
Belani, Chandra	PSCI-15-094	Molecular Analysis for Therapy Choice (MATCH)	Rebecca Hale 717-531-1003 pager 3657
<b>SYMPTOM MANAGEMENT/SUPPORTIVE CARE (None as of 05/17/2017)</b>			
<b>THORACIC</b>			
Wagner, Henry	PSHCI-09-078	Phase III Comparison of Thoracic Radiotherapy Regimens in patients with Limited Small Cell Lung Cancer Receiving Cisplatin and Etoposide ( <b>RTOG 0538</b> )	Rebecca Hale 717-531-1003 pager 3656
Belani, Chandra	PSHCI-14-065	A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination with Standard Doublet Therapy of Pemetrexed/Carboplatin in Patients with Stage IV (TNM M1a and M1b) Recurrent or Metastatic Non-Squamous Non-Small Cell Lung Cancer ( <b>Helix BioPharma</b> )	Rebecca Hale 717-531-1003 pager 3656
Belani, Chandra	PSHCI-14-067	A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (An ALCHEMIST Treatment Trial) ( <b>E4512</b> )	Rebecca Hale 717-531-1003 pager 3656
Belani, Chandra	PSHCI-14-088	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) ( <b>A151216</b> )	Rebecca Hale 717-531-1003 pager 3656
Belani, Chandra	PSHCI-14-093	Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)	Rebecca Hale 717-531-1003 pager 3656
Belani, Chandra	PSCI-16-093	Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab after Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers	Rebecca Hale 717-531-1003 pager 3656
<b>THORACIC</b>			
Belani, Chandra	PSHCI-14-055	Lung-MAP: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer	Rebecca Hale 717-531-1003 pager 3656
Belani, Chandra	PSHCI-15-033	Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer	Rebecca Hale 717-531-1003 pager 3656
Belani, Chandra	PSCI-15-094	Molecular Analysis for Therapy Choice (MATCH)	Rebecca Hale 717-531-1003 pager 3657
Belani, Chandra	PSHCI-15-107	A Phase I/II Study of Glembatumumab Vedotin in Patients with gpNMB-Expressing, Advanced or Metastatic Squamous Cell Carcinoma of the Lung	Rebecca Hale 717-531-1003 pager 3656
Belani, Chandra	PSHCI-16-028	Tissue and Blood Collection from Patients with Suspected Lung Cancer	Robin Walters 717-531-0003 ext 285229
Higgins, William	NCI-VN-Bronch	Piloting a Virtual Navigation (VN) System for Bronchoscopic Tissue Sampling	William Higgins 814-865-0186 ext 186

PI Name	Protocol No.	Title	CRC
<b>PEDIATRIC TRIALS</b>			
<b>BRAIN</b>			
McGregor, Lisa	COG-ACNS0332	Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Patients	COG Contact 717-531-6012
McGregor, Lisa	COG-ACNS0831	Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1-21 years	COG Contact 717-531-6012
Brown, Valerie	PSHCI-14-024	Molecular-Guided Therapy for the Treatment of Patients with Relapsed and Refractory Childhood Cancers ( <b>NMTRC</b> )	Kathryn Byrnes 717-531-3098; Suzanne Treadway 717-531-3097
McGregor, Lisa	PSHCI-15-003	A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 764038, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma	COG Contact 717-531-6012
<b>CORRELATIVE SCIENCE/BANKING</b>			
McGregor, Lisa	COG-ABTR01B1	A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens including Rare Pediatric Tumors.	COG Contact 717-531-6012
McGregor, Lisa	COG-ACCRN07	Protocol for the Enrollment on the Official COG Registry, the Childhood Cancer Research Network (CCRN)	COG Contact 717-531-6012
McGregor, Lisa	COG-ACNS02B3	A COG Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens	COG Contact 717-531-6012
McGregor, Lisa	COG-AEWS07B1	A Children's Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens	COG Contact 717-531-6012
McGregor, Lisa	COG-ANHL04B1	Rare and Cutaneous Non-Hodgkin Lymphoma Registry	COG Contact 717-531-6012
McGregor, Lisa	COG-AOST06B1	A COG Protocol for Collecting and Banking Osteosarcoma Specimens	COG Contact 717-531-6012
McGregor, Lisa	COG-AREN03B2	Renal Tumor Classification, Biology, and Banking Study	COG Contact 717-531-6012
McGregor, Lisa	COG-D9902	A COG Soft Tissue Sarcoma Biology and Banking Protocol	COG Contact 717-531-6012
<b>GI</b>			
McGregor, Lisa	COG-AHEP0731	Treatment of Children with All Stages of Hepatoblastoma	COG Contact 717-531-6012
<b>GU (None as of 05/17/2017)</b>			
<b>HEAD AND NECK (None as of 05/17/2017)</b>			
<b>HEMATOLOGY/OTHER</b>			
Greiner, Robert, J	PSCI-16-078	A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Venous-occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant	COG Contact 717-531-6012

PI Name	Protocol No.	Title	CRC
<b>LEUKEMIA</b>			
McGregor, Lisa	COG-AALL05B1	A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens	COG Contact 717-531-6012
McGregor, Lisa	COG-AALL08B1	Classification of Newly Diagnosed Acute Lymphoblastic Leukemia	COG Contact 717-531-6012
McGregor, Lisa	COG-AALL0932	Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)	COG Contact 717-531-6012
McGregor, Lisa	PSHCI-12-012	A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum ( <b>AALL1131</b> )	COG Contact 717-531-6012
McGregor, Lisa	PSHCI-14-094	A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy) ( <b>AALL1231</b> )	COG Contact 717-531-6012
Brown, Valerie	PSHCI-15-064	Phase I Study of Carfilzomib in Combination with Cyclophosphamide and Etoposide for Children with Relapsed and Refractory Solid Tumors and Leukemias	Kathryn Byrnes 717-531-3098; Suzanne Treadway 717-531-3097
Brown, Valerie	PSHCI-15-075	A Phase 2, Multi-center, Single-arm, Open-label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid®) in Pediatric Subjects 1 to ≤ 18 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia	Kathryn Byrnes 717-531-3098
McGregor, Lisa	PSCI-16-135	Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome	COG Contact 717-531-6012
<b>LYMPHOMA</b>			
McGregor, Lisa	PSHCI-15-010	A Phase III Randomized, Open Label, Multi-Center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated Asparaginase	COG Contact 717-531-6012
McGregor, Lisa	PSHCI-15-084	A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents	COG Contact 717-531-6012
<b>MDS</b>			
McGregor, Lisa	COG-AAML08B1	Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)	COG Contact 717-531-6012
<b>NEUROBLASTOMA</b>			
McGregor, Lisa	COG-ANBL00B1	Neuroblastoma Biology Studies	COG Contact 717-531-6012
Brown, Valerie	PSHCI-14-008	A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma ( <b>NMTRC</b> )	Kathryn Byrnes 717-531-3098; Suzanne Treadway 717-531-3097
McGregor, Lisa	PSHCI-14-085	Utilizing Response-and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma ( <b>ANBL1232</b> )	COG Contact 717-531-6012
Brown, Valerie	PSHCI-15-086	A Pilot Study Using Molecular Guided Therapy with Induction Chemotherapy Followed by Maintenance with DFMO for Subjects with Newly Diagnosed High-Risk Neuroblastoma	Kathryn Byrnes 717-531-3098; Suzanne Treadway 717-531-3097
Brown, Valerie	PSHCI-16-023	NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)	Kathryn Byrnes 717-531-3098; Suzanne Treadway 717-531-3097

PI Name	Protocol No.	Title	CRC
<b>OBSERVATIONAL</b>			
McGregor, Lisa	PSHCI-15-111	The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study	COG Contact 717-531-6012
<b>SARCOMA</b>			
McGregor, Lisa	PSHCI-12-077	A Phase II Trial of Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients with Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma ( <b>POETIC</b> )	COG Contact 717-531-6012
Brown, Valerie	PSHCI-14-073	A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors	COG Contact 717-531-6012
McGregor, Lisa	PSHCI-14-084	Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib ( <b>ARST1321</b> )	COG Contact 717-531-6012
McGregor, Lisa	PSHCI-15-031	Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma	COG Contact 717-531-6012
McGregor, Lisa	PSHCI-16-029	Phase II Study of Denosumab (NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma	COG Contact 717-531-6012
<b>SOLID TUMOR</b>			
Brown, Valerie	PSHCI-15-051	An Early-Phase, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of Anti-PD-L1 Antibody (MPDL3280A) in Pediatric and Young Adult Patients with Previously Treated Solid Tumors	Kathryn Byrnes 717-531-3098; Suzanne Treadway 717-531-3097
Brown, Valerie	PSHCI-15-064	Phase I Study of Carfilzomib in Combination with Cyclophosphamide and Etoposide for Children with Relapsed and Refractory Solid Tumors and Leukemias	Kathryn Byrnes 717-531-3098; Suzanne Treadway 717-531-3097
Brown, Valerie	PSHCI-15-087	A Phase I/II, Multicenter, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously Treated Solid Tumors	Kathryn Byrnes 717-531-3098; Suzanne Treadway 717-531-3097
<b>SYMPTOM MANAGEMENT/SUPPORTIVE CARE</b>			
McGregor, Lisa	COG-ALTE05N1	Umbrella Long-term Follow-up Protocol	COG Contact 717-531-6012
McGregor, Lisa	COG-ALTE07C1	Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer	COG Contact 717-531-6012